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Abstract
Clinical practice guidelines are used increasingly across medical specialties and settings, making evaluation of their utility
and validity a critical public health issue. In this paper, we describe some of the challenges that specialty organizations face
as they try to ensure that their guidelines are trustworthy and useful. We examine the practice guidelines for Major
Depressive Disorder recently published by the American Psychiatric Association (APA), identify five sources of potential
bias that may affect the guideline development process and offer suggestions based on our review. For example, even for
mild depression, this guideline privileges pharmacotherapy over other interventions, despite questions about the risk/benefit
ratio and the increasing concern over the iatrogenic harms of SSRIs and SNRIs. We compare recommendations from
international scientific groups (e.g. NICE) with those produced by specialty societies in an effort to demonstrate some of the
ways in which conflicts of interest, both intellectual and financial, may unduly influence guidelines.
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Introduction
Clinical practice guidelines (CPGs), designed to improve
healthcare outcomes, have been criticized for not
producing their intended result because of overly formulaic
care [1], wide variations in guideline quality [2] and
because they discourage concordance [3] and patient
insight [4]. Moreover, when ‘mono-disciplinary
specialists’ [5] develop CPGs, there is the risk that the
recommended courses of action may unduly reflect the
vested interests of the specialty groups that produce the
guidelines. Added to this bias are the financial conflicts of
interests, either of individual guideline authors or the
specialty society itself. Concerns about CPGs becoming
“marketing and opinion-based pieces” [6] have escalated
and in March of this year, the U.S. Institute of Medicine
(IoM) issued a report, “Standards for Developing
Trustworthy CPGs” [7]. There are numerous examples of
specialty groups producing guidelines that do not support,
or even contradict, recommendations made by disinterested
parties (see Table 1).
In this article, we describe some of the challenges
specialty organizations face as they try to assure their final
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product is balanced and accurate, citing some examples
(see Table 1). For further illustration, we also explore, in
depth, the practice guideline for Major Depressive
Disorder (MDD) recently published by the American
Psychiatric Association (APA) [17]. We have selected this
guideline for review because it is a prominent and trusted
resource in the U.S. and because its focus on the primacy
of pharmacotherapy differs from guidelines in other
countries (e.g. Canada and the UK). We make five
observations and offer suggestions based on our review.

Intellectual Conflict of Interest Challenge 1: Content Over Process
Guideline
development
groups
(GDG)
without
methodologists involved may be more likely to accept
research results at face value, especially if the results
confirm current beliefs [18]. Being a researcher does not
necessarily mean that one is trained in clinical
epidemiology and has expertise in interpreting evidence
from randomized controlled trials (RCTs) [19]. For
example, developers of the APA guideline consider all
The International Journal of Person Centered Medicine
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Table 1. Examples of Conflicting Guidelines
Topic
Treatment of patients
with diabetes

Screening for and
treatment of
subclinical
hypothyroidism

Conclusion from a scientific
group without self-interest
Insulin glargine does not offer any
benefit over less expensive insulin
products and should not be
included on provincial formularies
[8].
Screening and treatment should
not be routinely performed [10].

Screening of
newborns for hyperbilirubinemia

“The U.S. Preventive Services
Task Force (USPSTF) concludes
that the evidence is insufficient to
recommend screening infants for
hyperbilirubinemia to prevent
chronic bilirubin encephalopathy”
[12].

Breast cancer
screening in women
less than 50 years old

The USPSTF recommends against
routinely performing screening
mammography. There is at least
moderate certainty that the net
benefit is small [14].
“Do not use antidepressants
routinely to treat persistent
subthreshold depressive
symptoms or mild depression
because the risk-benefit ratio is
poor” [16].

Conclusion from a professional
society
Brand name-only Insulin glargine
should be used as an alternative
for generic long-insulin [9].

Reflected conflict of interest

Screening and treatment should
routinely be performed: “Although
good evidence is unavailable [to
support our recommendation],
there is a sizable amount of fair
evidence and an abundance of
opinion by experts . . . The
[scientific panel recommendations]
are contrary to the practice of
many. . . experts” [11].
“We recommend universal
predischarge bilirubin screening. .
., which helps to assess the risk of
subsequent severe
hyperbilirubinemia” [13].

Intellectual conflict of interest
(confirmation bias) and the duty of
the professional society to
represent the best interests of its
members.

Possible financial conflict of
interest of the individual guideline
writers or the specialty society.*

Intellectual conflict of interest
(confirmation bias) and the duty of
the professional society to
represent the best interests of its
members.

Annual screening beginning at age
40 for all women, at age 30 for
women at high risk [15].

Intellectual conflict of interest
(confirmation bias) and the duty of
the professional society to
represent the best interests of its
members.
Treatment of
Antidepressants are a first line
Intellectual conflict of interest
individuals with
treatment for patients with mild to
(confirmation bias) and the duty of
depression
moderate depression [17].
the professional society to
represent the best interests of its
members. Possible financial
conflict of interest of the individual
guideline writers or the specialty
society.
* The manufacturer of the product is a corporate partner and contributor of the CDA and almost all of the guideline developers have a
financial relationship with the manufacturer.

double-blind RCTs to be Level A evidence [17, p.103] and
do not address methodological issues such as duration,
study conduct or end-points (e.g. remission versus
reduction in symptoms) that can affect the quality of the
study.
Methodological experts are essential to a GDG
because they are better equipped than content experts or
researchers to address critical methodological issues and
questions that arise [20]. Given that the internal and
external validity of clinical research is quite variable and
dependent on a number of factors, uncritically accepting
meta-analyses and double-blind randomized controlled
trials is not a method for assuring an adequate evidence
base [21-23]. Approximately 75% of clinical trials
published in major journals are industry funded [24].
Given that the odds are 5.3 times greater than
commercially funded studies will support their sponsors’
products than non-commercially funded investigations,
study results should not be accepted at face value [21,
p.921].
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For example, one of the most commonly applied
intent-to-treat models - last observation carried forward
(LOCF) - can artificially bias results in favor of the study
drug [25,26]. This model assumes a randomization of
drop-outs that is not supported by any theory or data
[27,28] and it is also a model that fails to assess differences
in outcomes in patients who keep taking the drug [29]. The
high drop-out rates for participants enrolled in
psychotropic drug trials is a pernicious problem; average
drop-out rates of 50-64% have been reported in
antipsychotic studies and 37% in antidepressant (AD)
studies [28]. Thus, the appropriateness of using LOCF and
other analytic techniques to control for attrition is an
important methodological issue that deserves attention by
guideline developers when making recommendations about
efficacy of ADs. For example, Dubovsky and Dubovsky
[29] make a critical point that is not addressed in this
guideline: in many comparator trials, Selective Serotonin
Re-uptake Inhibitors (SSRIs) appeared to be at least as
effective as tricyclic ADs (TCAs). However, “because
The International Journal of Person Centered Medicine
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some TCAs such as imipramine are not as well tolerated
and more likely to be discontinued early, . . . for more
severely depressed patients who are more motivated to
continue it until it works, imipramine may be more helpful.
(Use of LOCF) misses the impact of adherence to
treatment” (italicization ours) [29, p.51].
All guideline development groups should include
content experts, but when specialty societies produce
CPGs, the majority of the panel should be composed of
individuals independent of the specialty group who have
expertise in methodology and epidemiology [30-32]. For
example, Germany’s approach to depression guideline
development began with the critical appraisal of
international guidelines for depression conducted by
multidisciplinary focus groups of experts in evidencebased medicine (EBM).

Intellectual Conflict of Interest Challenge 2: Confirmation Bias
A particular challenge in the guideline development
process is how to include, in the most accurate and
balanced way, the results of one’s own research. That is,
when a researcher designed, analyzed, or interpreted the
results of an RCT or meta-analysis he may have an implicit
bias toward the study and may not be as open to
considering questions about the study’s quality [33].
All members of the APA guideline committee are also
active researchers in major depressive disorder. The IoM
recommends that researchers and writers of systematic
reviews should not formulate guidelines [34-36]. The UK
National Institute for Health and Clinical Excellence
(NICE) allows researchers to participate in guideline
development, but further stipulates that, “understanding of
evidence-based medicine is essential” [16]. In keeping
with the IoM and NICE’s suggestions, in those instances
where a conflict is unavoidable and the expertise is
essential, individuals should recuse themselves when
assessing the studies for which they have served as PIs or
authors.

Intellectual Conflict of Interest Challenge 3: Acknowledging and
Addressing Controversies
Controversies or limitations to the available evidence
should be clearly outlined or reflected in guidelines. For
example, in the APA guideline, the iatrogenic harms of
pharmacologic treatment and the documented lack of
efficacy for patients with mild to moderate depression [3739] are not reflected fully in the weighing and
interpretation of evidence. There exists controversy about
the risk/benefit ratio of prescribing ADs as a first-line
intervention for mild to moderate depression [16,37,38,40],
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especially when it is a first episode. The controversy is due
to the increasing documentation of and concern about
adverse side effects [c.f. 41] and because most RCTs were
not adequately powered to address questions of efficacy of
AD use for mild depression [37, p.48]. Two wellpublicized meta-analyses independently concluded that
because of a lack of efficacy, AD medication should not be
the first line intervention for mild to moderate depression
[37,38]. In light of these results, “efforts should be made to
clarify to prospective clinicians and prospective patients
that . . . there is little evidence to suggest that . . .
(antidepressants) produce specific pharmacological benefit
for the majority of patients with less severe depression”
[37, p.32].
Although these meta-analyses are cited in the
guideline, the context in which they are referenced does
not provide the reader with a fully accurate understanding
of their conclusions. Instead, the following statement is
made in the guideline’s executive summary: “response
rates in clinical trials typically range from 50-75% of
patients, with some evidence suggesting greater efficacy
relative to placebo in individuals with severe depressive
symptoms as compared to those with mild to moderate
symptoms” [17, p.31]. Thus, the reader is left with the
erroneous impression that there is a clear evidence base for
the use of ADs for mild to moderate depression and that
ADs work even more effectively for severe depression.
This is not to suggest that ADs should never be
prescribed for mild or chronic sub-threshold depression;
certainly ADs have helped many people. However, for a
guideline on depression to be useful to clinicians it needs
to spell out more clearly under what conditions ADs
should be prescribed for mild episodes of depression and
for chronic sub-threshold depressive symptoms. Most
importantly, the risk/benefit issue of prescribing ADs
merits more detailed attention. For example, the citation of
a 50-75% response rate gives the impression that half to
three fourths of patients can expect a clinically meaningful
benefit of medication, a benefit that would likely be
perceived as substantial enough to outweigh concerns
about adverse side effects. What does not get addressed in
this guideline is the fact that the response rates are often
based on disease-oriented, not patient-oriented, outcome
measures and should not be conflated with remission. That
is, the effect size set by the UK National Institute for
Clinical Excellence (NICE) and used in depression trials is
0.5 or a drug/placebo difference of 3 points on the
Hamilton Depression Rating Scale [38]. Thus, the
statistically significant benefit reported in large RCTs is
best characterized as a disease-oriented outcome measure
and may not be clinically meaningful or relevant to
patients. Guideline readers may not be aware of the way in
which citing a response rate from large clinical trials can
inflate the absolute treatment effect [c.f. 3]. Patients have a
right to be fully informed about the likelihood and type of
benefit derived from taking a medication. Quoting
response rates without the appropriate context can obscure

The International Journal of Person Centered Medicine
Volume 1 Issue 4 pp 668-674

The International Journal of Person Centered Medicine

important information for both doctors and their patients as
they weigh the risks and benefits of taking an AD.
Thus, if a decision tree or hierarchy of interventions is
not provided, a clear and explicit explanation of possible
courses of action should be included to help guide the
clinician in decision-making. This recommendation is
consistent with the IoM’s requirement that CPGs “should
be articulated in a standard form detailing precisely what
the recommended course of action is and under what
circumstances it should be performed” [34].

Financial Conflict of Interest Challenge 1: Duty to the Group’s
Membership
Guidelines from specialty groups run the risk of
favoring new treatments and approaches, especially if their
use is limited primarily to that specialty or if the group’s
members played a large role in their development. The
APA guideline group limited their search of the literature
to articles published after the year 2000 and the authors
acknowledge a bias toward newer treatments based on
their methods. The bias toward “newer is better” is not
unique to psychiatry, but it is problematic in light of the
increasing concerns over the iatrogenic harms of SSRIs
and serotonin-norepinephrine reuptake inhibitors (SNRIs)
and the evidence of selective reporting of favorable results
[36,39].
To address the practice of selectively reporting
favorable results, guideline developers should review
unpublished studies. Additionally, they should consider the
role that publication bias may play (e.g. using funnel plots
to assess for publication bias) when assessing and rating
the strength of the evidence. This recommendation is
congruent with and extends the IoM requirement that
guideline developers establish “evidence foundations for
and rating strength of recommendations” [7].

Financial Conflict of Interest Challenge 2: When to Prohibit and
When to Manage Conflicts [42]
Growing financial relationships between all medical
subspecialties and industry have prompted congressional
inquiry, spurred new federal regulations on conflict of
interest (COI) and provided the rationale behind the
recently enacted Physicians Payment Sunshine Act [H.R.
3590, Section 6002]. During the time period of APA’s
CPG development, 100% of work group members reported
commercial ties to the companies that manufacture the
medications recommended in the guideline and all of the
members had multiple financial conflicts of interest. Other
guidelines have this issue [43,44], with groups such as
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NICE and the Canadian Network for Mood and Anxiety
Treatments allowing guideline developers to have financial
conflicts of interest as long as they were disclosed. The
APA attempted to mitigate the potential for bias by adding
a review panel that evaluated the guidelines for possible
industry influence (they concluded there was none). Yet at
least 2 of the 5 members of the independent panel had
industry ties they did not report. These financial
associations, most notably the fact that the chair and the
majority of the GDG members participated on speaker
bureaus, raise questions about the objectivity and integrity
of the guideline. Speakers Bureau participation is usually
prohibited (e.g. for faculty in medical schools), as it is
widely recognized to constitute a significant FCOI. The
pharmaceutical companies refer to individuals who serve
on Speakers Bureaus as “key opinion leaders” (KOLs),
because they are seen as essential to the marketing of both
diseases and drugs.
Moreover, there is no evidence to support the
assumption that only current financial associations with
industry affect behavior and some evidence suggests past
and/or the promise of future industry relationships may
exert a “pro-industry habit of thought” [45] or a “partisan
perspective in the medical literature” [46]. Therefore, we
recommend a rebuttable presumption of prohibiting
financial conflicts of interest among authors of practice
guidelines. In those circumstances where no independent
individuals with the requisite expertise are available,
individuals with associations to industry could serve as
consultants to the GDG, but they would not have decisionmaking authority about treatment recommendations [47].
Certainly, an independent review panel should have no
industry ties. In addition, there should be transparency of
the decision-making process by which an independent
review panel allows individuals with FCOI to serve on the
GDG.

Conclusion: producing useful and
trustworthy guidelines
“American medicine is seriously threatened by
conflicts of interest whose symptoms signal the
corruption of the medical mission and the
profession’s ideals.”[48].
Numerous studies in behavioral ethics and social
psychology [49-51] have demonstrated that it is part of the
human condition to have implicit biases - and remain
blissfully ignorant of them. Hence, it is unrealistic to
expect the guild of any service industry, on its own, “to
harness its self-interest and to act according to beneficence
alone” [52]. Medicine is no different. These suggestions to
avoid conflicts of interest are not difficult to implement
[53]. They are feasible and necessary and in light of the
fact that “various medical interventions are directly
contributing to the burden of illness” [54], the stakes are
The International Journal of Person Centered Medicine
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high. Therefore, in order to restore public trust and
integrity in medicine and ensure unbiased, evidence-based
practice, it is critical to prohibit certain conflicts and better
manage others. If these safeguards are not put in place,
perhaps it is time to call a moratorium on medical specialty
groups producing guidelines.
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